secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001104659-25-122564
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix enters quiet period for SOL-1 Phase 3 trial; data on track Q1 2026
--------------------------------------------------------------------------------

- Quiet period for SOL-1 Phase 3 trial of AXPAXLI (wet AMD) begins December 20, 2025.
- Next investor communication expected early February 2026 with Q4/FY2025 results.
- SOL-1 data remain on track for release in the first quarter of 2026.
- No financial results or clinical data provided; no exhibits attached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/0001104659-25-122564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/tm2533889d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer